Multiple Sclerosis Clinical Trials in San Antonio

Showing 381-400 of 435 trials

Study to Evaluate the Effects of Synthetic Conjugated Estrogens, B (SCE-B) on Nocturnal Vasomotor Symptoms in Postmenopausal Women

NCT00592839

This is a multi-center study to evaluate the effects of SCE-B on nocturnal vasomotor symptoms. Study duration will be approximately 16 weeks; this includes a 4-week screening period and approximately 5 scheduled clinic visits. Participants will receive one of two strengths of SCE-B tablets plus matching placebo or placebo only, and will have a physical and gynecological exams that may include transvaginal ultrasound, endometrial biopsy and a pap smear. Participants will be asked to wear a monitoring device for a portion of the study and be asked to complete a daily dairy.

Nocturnal Vasomotor Symptoms

Duramed Research157 participantsStarted Dec 2007

Anaheim, California, United States • Sacramento, California, United States • San Diego, California, United States +14 more locations

COMPLETEDPhase 1< 1 mile

Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors

NCT00195260

To evaluate the safety and tolerability of oral SKI-606 (bosutinib) administered on a daily schedule to subjects with advanced malignant solid tumors and to define a maximum tolerated dose (MTD) in this subject population.

Neoplasms

Pfizer151 participantsStarted Oct 2004

Birmington, Alabama, United States • Scottsdale, Arizona, United States • Los Angeles, California, United States +16 more locations

Study to Evaluate the Effects of Synthetic Conjugated Estrogens, B (SCE-B) on Nocturnal Vasomotor Symptoms in Postmenopausal Women

Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors

Multiple Sclerosis Trials in Other Cities

A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer

Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program

Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer

First-in-human Study of AB0024 to Evaluate Safety and Tolerability in Adults With Advanced Solid Tumors

Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy

Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy

Intrathecal Gemcitabine to Treat Neoplastic Meningitis, IT Gemcitabine

Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer

Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer

Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor

A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

A Study of E7389 in Advanced/Metastatic Breast Cancer Patients

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine

YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy

Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients

Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Other Conditions in San Antonio